Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome – Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental impairments, with no currently approved medicines that address the underlying cause of the disease – CAMBRIDGE, Mass. and BEDFORD, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: B...
Minerals Technologies Inc. Announces Participation at Upcoming Investor Conferences NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI”) today announced its participation at two upcoming investor conferences: August 19, 2025: Seaport Research Partners’ Annual Summer Conference (virtual)September 4, 2025: Jefferies’ Industrials Conference (in-person in New York, NY) – Douglas T. Dietrich, Chairman and Chief Executive Officer, will present at 3:30pm ET in addition to participating in one-on-ones with individual investors. MTI will be represented by Do...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.